Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (13738)	6/1/2000 11:46:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

If the data show no promise a release now or later would be the same. But suppose the data are, "compelling" but because of this being a 4 armed trial with only 33 deaths out of 393 subjects that statistical significance is not the 95% confidence level. If 14 have died in the treatment group and 19 in the placebo group, I would rather have a peer reviewed article explaining the data and perhaps Dr.Giroirs earlier statements regarding potential for better results in actual use rather than a trial situation, because of timing of use being delayed in a trial. Once "we" look for support the other side does not just roll over. They will simply point out that "we" are shareholders and unfortunately the data were not statistically significant. IMO the management of XOMA and Baxter are doing what is best.